What is a primary consideration when administering methotrexate?

When administering methotrexate, monitoring liver function is a primary consideration due to the drug's potential hepatotoxic effects. Methotrexate is an antimetabolite used in the treatment of various conditions, including certain cancers and autoimmune diseases. It can lead to liver toxicity, particularly in patients receiving long-term treatment or high doses. Regular liver function tests allow for early identification of possible hepatotoxicity, enabling timely interventions to prevent further liver damage.

The other considerations may also play a role in a comprehensive care plan, but they are not as critical as monitoring liver function specifically for methotrexate. Continuous infusion is generally not required for methotrexate administration unless specific clinical scenarios dictate it. While renal clearance is important to consider since methotrexate is primarily excreted by the kidneys and renal impairment can lead to increased toxicity, liver function remains a fundamental focus due to the direct impact on therapy management and patient safety. Cardiac output assessment is less relevant in the context of methotrexate administration.